Does DYN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for DYN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does DYN stock do?

Clinical-stage biotechnology firm developing targeted therapeutics for rare, genetically driven muscle diseases using its proprietary FORCE delivery platform. Currently pre-revenue with zero commercial product sales.

What is DYN stock's price target?

This cached page does not contain a precise model fair value for DYN.

The TradeMates model verdict for DYN is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.

Is DYN a good dividend stock?

DYN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

DYN (DYN) Stock Analysis

Q: Is DYN stock a good investment?

The cached TradeMates AI model rates DYN as AVOID with an investment score of 37/100. Pre-revenue clinical-stage biotech with $893.4M in cash facing accelerating annual cash burn (-$405.1M FCF in 2025) and heavy corporate insider selling. Highly speculative outlook contingent on clinical trial readouts. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Dyne's $893M cash funds FORCE platform trials into 2028, but accelerating burn and heavy insider dumping make risk/reward unfavorable.

Investment score: 37/100

Pre-revenue clinical-stage biotech with $893.4M in cash facing accelerating annual cash burn (-$405.1M FCF in 2025) and heavy corporate insider selling. Highly speculative outlook contingent on clinical trial readouts.

Peers

VKTX
GRAL
LEGN
ARQT
DNLI

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
VKTX	-6.48	8.57	0.00	-6.36	—	0.00
GRAL	-8.01	1.32	20.28	-8.21	—	-2.37
LEGN	-35.22	2.68	2.56	-395.10	—	-0.07
ARQT	113.87	14.88	6.78	73.08	—	0.06
DNLI	-7.23	4.60	903.64	-6.20	—	-141.91

View the full interactive analysis